Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF Therapy Comparing Syringe Preparation Time Using Ranibizumab Vial and Pre-filled Syringe
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 18 Apr 2018 Planned End Date changed from 30 Sep 2018 to 1 Jun 2019.
- 18 Apr 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Feb 2019.
- 18 Apr 2018 Status changed from not yet recruiting to recruiting.